Poor
Needs Major Revision
Patient Risk:
High
Summary
Partially matches label-supported indications and mechanism at a high level, but includes multiple label-noncompliant assertions (notably 'irreversibly binding' and 'prevents absorption' wording) and adds extensive pricing/savings program details and comparative drug examples not supported by the provided label excerpts. Adverse reaction frequency claims are also not supported by the provided adverse reactions excerpt.
Category Scores
Accurate Statements
LOKELMA is a prescription medication used to treat hyperkalemia.
Supported by label Indications and Usage: "LOKELMA is indicated for the treatment of hyperkalemia in adults."
LOKELMA contains sodium zirconium cyclosilicate.
Supported by label Description (11).
Sodium zirconium cyclosilicate is a selective potassium binder.
Supported by label Description (11) stating it is a potassium binder and by mechanism context (12.1).
LOKELMA facilitates removal of potassium from the body through feces.
Supported by label 12.1 (increases fecal potassium excretion via binding in GI lumen) and 12.3 (recovered in feces; no evidence of systemic absorption).
Unsupported Statements
LOKELMA works in the gastrointestinal tract by irreversibly binding to potassium ions.
Label 12.1 supports preferential capture/binding in the GI lumen but does not use or support the wording 'irreversibly binding' in the provided excerpts.
Irreversible binding of potassium ions by LOKELMA prevents their absorption into the bloodstream.
Label supports lack of systemic absorption/no evidence of systemic absorption (12.3) and fecal recovery, but the provided label excerpts do not support the specific causal framing 'irreversible binding' or explicit wording 'prevents their absorption into the bloodstream' as stated.
A 5-gram packet of LOKELMA powder for oral suspension typically costs around $100 to $120 without insurance.
No pricing information is present in the provided label sections.
The cost of LOKELMA can vary depending on factors such as insurance coverage, pharmacy, and dosage.
No cost/price variability information is present in the provided label sections.
Patient assistance programs and savings cards may be available to help reduce the out-of-pocket cost of LOKELMA for eligible individuals.
No patient assistance/savings program information is present in the provided label sections.
The LOKELMA Savings Card program offers eligible patients a savings of up to $300 on each prescription.
No savings card program specifics are present in the provided label sections.
The LOKELMA Savings Card program has a maximum annual savings of $3,600.
No savings card program specifics are present in the provided label sections.
Eligibility for LOKELMA savings programs often depends on insurance status and income.
No eligibility criteria for savings programs are present in the provided label sections.
The most common side effects associated with LOKELMA include diarrhea, constipation, nausea, and vomiting.
The provided adverse reactions excerpt (6) lists only 'Edema' and does not support these as the most common side effects.
Other medications used to manage hyperkalemia include potassium binders like patiromer (Veltassa).
No alternative/comparator medication discussion is present in the provided label sections.
Other medications used to manage hyperkalemia include older agents such as sodium polystyrene sulfonate (Kayexalate, Kionex).
No alternative/comparator medication discussion is present in the provided label sections.
Contradictions
Important Omissions
Dosage and administration instructions for LOKELMA (e.g., dosing regimen, reconstitution/dosing timing details).
Importance:
High
Key safety information from warnings/precautions and contraindications (e.g., label warnings and any relevant precautions).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Includes multiple statements not supported by the provided label excerpts (mechanism wording 'irreversibly' and 'prevents absorption' framing; adverse reaction frequency as 'most common'; and non-label pricing/savings details). The inclusion of non-label operational/marketing information may crowd out label safety communications; the provided response also omits dosage and key safety sections, which are material for safe and accurate prescribing.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Major Revision
Primary Issue
Non-label/unverified content (pricing/savings programs and comparative drugs) plus mechanism wording not supported by label language and unsupported 'most common' adverse reaction claims; also missing dosage/safety details.
Suggested Improvement
Restrict claims to label-supported wording from Indications, Description/Mechanism (12.1), and Safety sections; remove pricing/savings program and comparator drug statements unless included in the FDA label; do not characterize binding as 'irreversible' or absorption as 'prevented' unless the label explicitly states that phrasing; avoid asserting 'most common' adverse reactions without label support; include dosage/administration and relevant warnings/precautions from the label when making therapeutic-safety communications.